

## NEW UV SPECTROPHOTOMETRIC METHOD FOR THE DETERMINATION OF CEFPODOXIME IN PHARMACEUTICALS BY FIRST DERIVATIVE METHOD

Santosh Raveendra Karajgi\*, Ashwini Rajendra Wadekar, Ramaling Bhagavantrao Kotnal, Navanath Vishwanathappa Kalyane

BLDEA's College of Pharmacy, Vijaypur - 586103, India

\*Corresponding Author: Email: [santosh.karajgi@gmail.com](mailto:santosh.karajgi@gmail.com)

Received: 30 April 2016 / Revised: 31 May 2016 / Accepted: 21 June 2016 / Available online : 30 June 2016

### ABSTRACT

The spectrophotometric method for estimation employed first derivative spectrophotometric method for analysis using methanol as solvent for the drug. Cefpodoxime proxetil has absorbance maxima at 235nm and obeys Beer's law in concentration range 10-50µg/ml. The recovery studies ascertained accuracy of the proposed method; result validated according to ICH guideline. Results were found satisfactory and reproducible. The method was successfully for evaluation of Cefpodoxime proxetil in tablet dosage form without interference of common excipients.

**Keywords** – Cefpodoxime Proxetil, First derivative, UV spectrophotometric, Estimation.

### 1. INTRODUCTION

Cefpodoxime Proxetil is an oral third generation cephalosporin antibiotics. It is active against most Gram positive and Gram negative organisms. The antibacterial action of Cefpodoxime Proxetil is through inhibition of bacterial cell wall synthesis probably by acylation of membrane bound trans peptidase enzymes; this prevents cross linkage of peptidoglycan chains, which is necessary for bacterial cell wall strength and rigidity. It is commonly used to treat acute otitis media, pharyngitis, and sinusitis<sup>1</sup>. So far, thirteen methods are reported for the determination of Cefpodoxime in dosage forms. Of these methods, eight methods are by HPLC determination<sup>2-6</sup> four UV-Spectrophotometric methods by zero order method<sup>7,8</sup> and one method by Hydrotropic Solubilization method<sup>9</sup>. No First derivative UV Spectrophotometric method for routine determination of this drug was reported and there for; aim of the present study was to develop an accurate, simple, economical First derivative UV spectrophotometric method for the rapid determination of Cefpodoxime in individual bulk drugs and tablet formulations.




Fig. 1 : Chemical structure of Cefpodoxime

## 2. Materials and Methods


### 2.1 Materials

Shimadzu 1800 spectronic UV spectrophotometer Instrument, a pair of 1cm path length quartz cells and Methanol (95%) as the solvent were used for the study. Tablet brands for the assay studies were obtained from the local market.

### 2.2 Methodology

#### 2.2.1 Determination of amplitude at zero crossing point for the selection of wavelength

Standard stock solution of Cefpodoxime proxetil were prepared by dissolving accurately weighed quantities (25 mg) in 25ml of methanol and transferred it to 25ml volumetric flask. Volume was adjusted with methanol to obtain stock solution 1000 $\mu$ g/ml concentration. For obtaining clear solution was ultra-sonicated. Dilutions were done to get concentration of 10 $\mu$ g/ml. The standard solution of Cefpodoxime proxetil (10 $\mu$ g/ml) was scanned at wavelength range of 220nm to 280nm keeping N=5 and the amplitude were found to be 0.005 with zero crossing point at 235nm. (Figure 2). There for, 235nm was selected analytical wavelength for the determination of Cefpodoxime in bulk drugs and pharmaceutical formulations.



**Figure 2:** First derivative spectrum of Cefpodoxime 10 $\mu$ g/ml


#### 2.2.2 Linearity

Standard stock solution of Cefpodoxime proxetil, relevant amount of solution was pipette out into 25ml volumetric flasks and dilutions were made with methanol to be working standard solutions of concentrations 10, 20, 30, 40, 50 $\mu$ g/ml. The difference in amplitude of Cefpodoxime proxetil were measured in the first derivative mode with N=5 of instrument at 235nm. The calibration curve of drugs was plotted


The concentration range over which the drugs followed linearity was chosen as an analytical concentration range i.e. 10-50 $\mu$ g/ml for Cefpodoxime. (Table 1 and Figures 3 to 8)

**Table 1: Calibration Data for Cefpodoxime by First Order Derivative Method**


| Sr. No | Conc. (µg/ml) | Amplitude |
|--------|---------------|-----------|
| 1.     | 10            | 0.005     |
| 2.     | 20            | 0.009     |
| 3.     | 30            | 0.012     |
| 4.     | 40            | 0.015     |
| 5.     | 50            | 0.019     |




**Figure 3:** First order derivative calibration plot for Cefpodoxime




**Figure 4:** First derivative spectrum of Cefpodoxime 10µg/ml




**Figure 5:** First derivative spectrum of Cefpodoxime 20µg/ml



**Figure 6:** First derivative spectrum of Cefpodoxime conc. 30µg/ml



**Figure 7:** first derivative spectrum of cefpodoxime 40µg/ml



**Figure 8:** first derivative spectrum of cefpodoxime 50µg/ml

### 2.3 Validation of the proposed method

#### A) Evaluation of drug from dosage form (Tablet assay study):

Standard:

Standard stock solutions having 1000µg/ml of Cefpodoxime proxetil was prepared by dissolving 2.5mg of drug in 25ml methanol to get the final concentration of 20µg/ml. Dilutions of standard stock solution were made using methanol. This were scanned at 235nm and with derivative mode N=5.

Sample:

Twenty tablets of brand Gudcef 200 and Cefpodem 200 containing 200mg of Cefpodoxime proxetil weighed; powered respectively. Amount of powder sample equivalent to 100mg Gudcef 200 brand and 100mg Cefpodem 200 brand of Cefpodoxime proxetil was taken and dissolved in methanol using volumetric flask respectively. Dilutions were done to get concentration 20µg/ml of Cefpodoxime proxetil. These concentration was scanned at 235nm and with derivative mode N=5. (Table 2)

**Table 2:** Assay of Cefpodoxime in tablet formulation Gudcef 200 and Cefpodem 200 by first order derivative method

| Brand Name | Label Claim (mg/tab) | Amount Found (mg/tab) | % Or Label Claim | Mean  | SD    | CV     |
|------------|----------------------|-----------------------|------------------|-------|-------|--------|
| GUDCF      | 200                  | 200.01                | 100.00           | 99.59 | 0.411 | 0.1693 |
|            | 200                  | 199.45                | 99.72            |       |       |        |
|            | 200                  | 199.80                | 99.90            |       |       |        |
|            | 200                  | 198.75                | 99.37            |       |       |        |
|            | 200                  | 198.01                | 99.00            |       |       |        |
| CEFPODEM   | 200                  | 200.00                | 100.00           | 99.61 | 0.322 | 0.1040 |
|            | 200                  | 199.06                | 99.53            |       |       |        |
|            | 200                  | 198.50                | 99.25            |       |       |        |
|            | 200                  | 199.80                | 99.90            |       |       |        |
|            | 200                  | 198.80                | 99.40            |       |       |        |

*\*Mean of three determinations*

## B. Accuracy (Recovery Study)

Accuracy was analysed by recovery experiments. By adding known amounts of powdered tablet in pure drug then experiments of recovery were performed. The recovery was carrying out at three levels, 80%, 100% and 120% of Cefpodoxime proxetil standard concentration.

By using above procedure three accuracy samples were prepared for each accuracy level. Solution were analysed; the % recoveries were calculated by using formula

$$\% \text{ Recovery} = \frac{\text{Observed amount of compound in sample}}{\text{Amount of all compound present in sample}} \times 100$$

The recovery values are summarized in following tables 3 and 4.

**Table 3:** Accuracy parameter of Cefpodoxime for Brand Gudcef 200

| Level of % Recovery | *Amount Present (mg) | Amount Of Stand. Added (mg) | Total Amount Recovered (mg) | % Recovery | %mean Recovery | SD    | CV    |
|---------------------|----------------------|-----------------------------|-----------------------------|------------|----------------|-------|-------|
| 80                  | 200                  | 160                         | 158.68                      | 99.18      | 99.626         | 0.460 | 0.212 |
| 80                  | 200                  | 160                         | 160.16                      | 100.10     |                |       |       |
| 80                  | 200                  | 160                         | 159.36                      | 99.60      |                |       |       |
| 100                 | 200                  | 200                         | 199.64                      | 99.82      | 99.590         | 0.608 | 0.370 |
| 100                 | 200                  | 200                         | 500.10                      | 100.05     |                |       |       |
| 100                 | 200                  | 200                         | 197.80                      | 98.90      |                |       |       |
| 120                 | 200                  | 240                         | 238.32                      | 99.30      | 99.663         | 0.489 | 0.239 |
| 120                 | 200                  | 240                         | 240.52                      | 100.22     |                |       |       |
| 120                 | 200                  | 240                         | 238.72                      | 99.47      |                |       |       |

**Table 4:** Accuracy parameter of Cefpodoxime for Brand Cefpodem 200

| Level of % Recovery | *Amount Present (mg/ml) | Amount Of Stand. Added (mg/ml) | Total Amount Recovered (mg/ml) | % Recovery | % mean Recovery | SD    | CV    |
|---------------------|-------------------------|--------------------------------|--------------------------------|------------|-----------------|-------|-------|
| 80                  | 200                     | 160                            | 159.76                         | 99.85      | 99.700          | 0.455 | 0.207 |
| 80                  | 200                     | 160                            | 158.84                         | 99.28      |                 |       |       |
| 80                  | 200                     | 160                            | 160.28                         | 100.18     |                 |       |       |
| 100                 | 200                     | 200                            | 198.02                         | 99.01      | 98.706          | 0.614 | 0.377 |
| 100                 | 200                     | 200                            | 196.00                         | 98.00      |                 |       |       |
| 100                 | 200                     | 200                            | 198.22                         | 99.11      |                 |       |       |
| 120                 | 200                     | 240                            | 240.16                         | 100.07     | 99.630          | 0.385 | 0.148 |
| 120                 | 200                     | 240                            | 238.44                         | 99.35      |                 |       |       |
| 120                 | 200                     | 240                            | 238.72                         | 99.47      |                 |       |       |

## C. Precision

The precision (inter-day) was evaluated by carrying four independent samples of Cefpodoxime proxetil with four different analysts in the same laboratory. The precision values obtained by four analysts were summarized in table.5.

**Table 5:** Precision of Cefpodoxime for first derivative method

| Sample Number | Assay of Cefpodoxime %of labelled amount ( Inter-day precision) |            |             |            |
|---------------|---|------------|-------------|------------|
|               | Analyst I   | Analyst II | Analyst III | Analyst IV |
| 1             | 99.40   | 100.26     | 99.20       | 100.00     |
| 2             | 100.05  | 99.74      | 99.79       | 99.09      |
| 3             | 98.25   | 99.02      | 100..17     | 98.99      |
| 4             | 99.67   | 98.97      | 99.44       | 100.08     |
| Mean          | 99.34   | 99.49      | 99.65       | 99.54      |
| S.D.          | 0.775   | 0.618      | 0.422       | 0.579      |
| CV            | 0.601   | 0.382      | 0.178       | 0.336      |

### 3. RESULTS AND DISCUSSION

The standard solutions of Cefpodoxime in Methanol (10µg/ml each) subjected to a scan at the series of wave-lengths of 220nm to 280nm at First order derivative spectra were taken at N=5 using Shimadzu 1800 spectronic UV-Visible spectrophotometer. And amplitude found to be 0.005 The calibration curve of Cefpodoxime was found to be linear at conc. Range 10µg/ml to 50µg/ml at 235nm. There for, it was clear that Cefpodoxime can be determined in presence of methanol with no intervention of any irrelevant substance in pharmaceutical products.

With the intention of determining the practicability of the developed technique for the assessment of commercially available brands (GUDCEF-200 and CEFPODEM-200) of medicinal formulations, the technique was initially attempted on bulk drugs in their synthetic mixture sample as well as concentrations were estimated. Then the technique was subjected to the assay of in marketed dosage forms and satisfactory conclusions were attained within the acceptable limits as per the content of the label claim for Cefpodoxime.

The newly developed method was validated as per the international guidelines and parameters. The novel method for the quantitative investigation of Cefpodoxime was subjected to different validation parameters like selectivity and specificity in presence of formulation additives and excipients, studied for Linearity and range at different levels of concentrations and calibration standards where the determination range was optimized, accuracy was proved by recovery studies at different concentration levels, precision was established through inter day precision studies, where the samples were subjected to changed conditions other than optimized parameters.

### 4. CONCLUSION

It can be concluded that the proposed newly developed First derivative method is a rapid, economical, reproducible, accurate and precise method for the routine determination of Cefpodoxime in its single component synthetic bulk drug form as well as commercial tablet formulations; economically alternative to HPLC and better than UV-spectrophotometric methods zero crossing methods.

### 5. REFERENCES

1. <https://en.wikipedia.org/wiki/Cefpodoxime>.
2. Darji BH, Shah NJ, Patel AT, Patel NM, Development and validation of a HPTLC method for the estimation of Cefpodoxime Proxetil, Indian Journal of Pharmaceutical Sciences, 2007, 69 (2): 331-333.
3. Mostafa NM, Fattah LA, Weshahy SA, Hassan NY, Boltia SA, Stability indicating methods for the determination of Cefpodoxime Proxetil in the presence of its acid and alkaline degradation products, Indian Journal of Pharmaceutical and Biological Research, 2013, 3 (6): 223-239.

4. Kamalesh G, Madhuri D, Nagarajan G, Stability indicating method development, degradation studies and validation of Cefpodoxime proxetil by RP-HPLC method, International Journal for Pharmaceutical Research Scholars, 2014, 3(4): 269-275.
5. Mathew C, Ajitha M, Satheshbabu PR, Cefpodoxime proxetil: a new stability indicating RP-HPLC method, Chromatograph, 2013, 1-8.
6. Patel G, Rajaput S, Stress degradation studies on Cefpodoxime proxetil and development of a validated stability indicating HPLC method, Pharmaceutical methods, 2012, 3(2): 117-120
7. Bushra MU, Islam KR, Hossain MS, Sarah AH, Method development and validation of Cefpodoxime proxetil in bulk and pharmaceutical formulation by using UV spectrophotometer, International Journal of PharmTech Research, 2014, 4(1): 817-824.
8. Siddalinga swamy MS, Shetty ASK, Anil kumar SM, UV-Visible spectrophotometric method for the estimation of Cefpodoxime proxetil in bulk drug and pharmaceutical dosage form, International Journal of PharmTech Research, 2012, 4(2): 750-756.
9. Asnani G, Jadhav K, Dhamecha D, Sankh A, Patil M, Development and validation of spectrophotometric method of Cefpodoxime proxetil using hydrotropic solubilizing agents, Pharmaceutical methods, 2012, 3(2): 117-120.